This company develops and produces biosimilar products, ethical drugs, over the counter drugs, and other related products. They have a diverse pipeline of biosimilars that treat different diseases and disorders through multiple therapeutic modalities.
Latest News
- In the afternoon of the 5th, Samsung Electronics, Mirae Asset Securities, Yuhan Corporation, Celltri.. - 매일경제
- Herceptin Biosimilar Market Future Business Opportunities - openPR
- Celltrion's Steqeyma nabs FDA approval as seventh Stelara biosimilar - Healio
- FDA Approves Steqeyma: The Seventh Stelara Biosimilar - The Center for Biosimilars
- FDA nod for Celltrion's Steqeyma - The Pharma Letter
- Celltrion Is Latest To Snag A US Stelara Rival - Citeline News & Insights
- Celltrion's Crohn's treatment set for February U.S. release - MSN
- Biosimilars landscape in South Korea - The Pharma Letter
- Celltrion leads biosimilars deals landscape in South Korea, finds GlobalData - Express Pharma
- Celltrion's Crohn's treatment set for February U.S. release - The Korea JoongAng Daily
- Celltrion earns spot in Dow Jones Sustainability World Index for ESG excellence - 조선비즈 - 조선비즈
- Celltrion gets approval of Steqeyma from FDA - Korea Economic Daily
- Celltrion's Zymfentra wins nod for rheumatoid arthritis phase 3 trial in Europe - KBR
- U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) - BioSpace
- U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) - The Manila Times
